NAUT

Nautilus Biotechnolgy, Inc. (NAUT) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Business Quality

NAUT remains deeply unprofitable with negative TTM margins and returns, including gross margin of -9.2%, operating margin of -330.4%, and ROIC of -39.5%.

Revenue generation is still extremely limited relative to valuation, with revenue per share of 0.0015 and EV/sales of 721.3x.

The balance sheet remains liquid, with a current ratio of 10.1x and cash ratio of 1.52x, but this does not offset the weak operating profile.

Financial Strength

Liquidity is strong, with current ratio at 10.1x and cash per share of 0.66.

Debt appears manageable, with debt-to-equity at 0.21x and net debt to EBITDA at -0.27x.

However, operating cash flow and free cash flow remain negative, and cash conversion is still poor despite the strong working capital position.

Growth Runway

There is no evidence of scalable growth yet, as asset turnover remains extremely low at 0.0012x and revenue per share is minimal.

Heavy spending intensity relative to revenue, including R&D-to-revenue of 208.0% and SG&A-to-revenue of 128.7%, suggests the company is still in an early, unproven commercialization phase.

No recent news indicates a new growth catalyst or demand inflection.

Valuation

Valuation remains highly stretched on sales, with EV/sales at 721.3x and price/sales at 644.2x.

Traditional earnings and cash-flow multiples are not meaningful support because TTM earnings and free cash flow are negative.

Book-value support is limited, with price/book at 0.93x, but this is outweighed by the lack of profitability and weak cash generation.

Risk Profile

The main risks remain persistent losses, negative cash flow, and extremely high operating expense intensity relative to revenue.

The company does have a strong liquidity cushion, which reduces near-term solvency risk.

No new litigation, financing, or regulatory risk emerged this month.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nautilus Biotechnolgy, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →